Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265315 | 1.00 | CYP2C19 (0.56) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL3265138 | 1.00 | CYP2C19 (0.56) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL193009 | 0.87 | ATM (0.60) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL203326 | 0.87 | ATM (0.60) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL194384 | 0.87 | ATM (0.60) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL23346140 | 0.84 | CYP2C9 (0.51) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL16938797 | 0.84 | CYP2D6 (0.51) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL16592951 | 0.84 | CYP2D6 (0.42) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL16729074 | 0.84 | CYP2C9 (0.51) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL18653054 | 0.84 | CYP2D6 (0.51) | CYP2C19CYP2C9CYP2D6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200231573-A1 | Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating HCV-Related Disease | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2020-07-23 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| US-7659270-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2C19 180/4885CYP2C9 324/4885CYP2D6 497/4885 |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CYP2C19 3298/4885CYP2C9 3296/4885CYP2D6 2617/4885 |
| US-20200231573-A1 | Fluorene Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor, and Pharmaceutical Composition Comprising Same as Effective Ingredient for Preventing or Treating HCV-Related Disease | SLC10A1, SLC39A11, FAR1 | CYP2C19 1904/4885CYP2C9 1707/4885CYP2D6 2295/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP2C19 3298/4885CYP2C9 3296/4885CYP2D6 2617/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2C19 3369/4885CYP2C9 2585/4885CYP2D6 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.